## 2023 NHSN Pneumonia (PNEU) Checklist

Pneumonia (PNEU) Summary		
Criterion	Criterion Met	Date of Event (DOE)
PNU1 (patients of any age)		
PNU1 (infants ≤ 1 year old)		
PNU1 (child > 1 year old or ≤ 12 years old)		
PNU2 (Pneumonia with Common Bacterial or		
Filamentous Fungal Pathogens and Specific		
Laboratory Findings)		
PNU2 (Viral, Legionella, and other Bacterial		
Pneumonias with Definitive Laboratory		
Findings)		
PNU3 (Immunocompromised Patients)		
Please refer to <u>Chapter 6 Pneumonia (PNEU) Event</u> of the Patient Safety Manual for additional information.		

**NOTE**: The PNEU Algorithms (PNU1,2,3) include <u>FOOTNOTE</u> references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.



December 2011 - December 2111		
Documentation Review Checklist		
Pneumonia 1 (PNU1)		
Must meet at least <u>one</u> of the following criteria:		
PNU1: ANY PATIENT, any age group		
Element	Element Met	Date
Patient has <i>one of the following</i> found in two or more serial chest imaging test results 1.2.14:		
Either new and persistent <b>OR</b> progressive and persistent		
Infiltrate		
Consolidation		
Cavitation		
<ul> <li>Pneumatoceles, in infants ≤ 1 year old</li> </ul>		
NOTE: In patients without underlying pulmonary or cardiac disease (such as respiratory distress s	undrome	
bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), one of		nest imaaina
test result is acceptable $\frac{1}{2}$ .	<u> </u>	est imaging
AND Patient has at least <i>one</i> of the following:		
• Fever (> 38.0°C or > 100.4°F)		
Leukopenia (≤ 4,000 WBC/mm³)		
Leukocytosis (≥ 12,000 WBC/mm³)      Leukocytosis (≥ 12,000 WBC/mm³)		
<ul> <li>Adults ≥ 70 years old, altered mental status with no other recognized cause</li> </ul>		
AND Patient has at least <u>two</u> of the following:		
<ul> <li>New onset of purulent sputum<sup>3</sup> or change in character of sputum<sup>4</sup>, or increased</li> </ul>		1
respiratory secretions, or increased suctioning requirements		
New onset or worsening cough, or dyspnea, or tachypnea <sup>5</sup> New onset or worsening cough, or dyspnea, or tachypnea <sup>5</sup>		
Rales <sup>6</sup> or bronchial breath sounds		
<ul> <li>Worsening gas exchange (for example: O₂ desaturations (for example, PaO₂/FiO₂ ≤ 240)², increased oxygen requirements, or increased ventilator demand)</li> </ul>		
PNU1: ALTERNATE CRITERIA, for infants ≤ 1 year old		
Element	Element	Date
	Met	
Patient has <i>one of the following</i> found in two or more serial chest imaging test results 1.2.14:		
Either new and persistent <b>OR</b> progressive and persistent		
Infiltrate		
<ul> <li>Consolidation</li> </ul>		
Cavitation		
Pneumatoceles, in infants ≤ 1 year old		 ]
NOTE: In patients <b>without</b> underlying pulmonary or cardiac disease (such as respiratory distress substructive pulmonary disease), one of test result is acceptable $\frac{1}{2}$ .		nest imaging
AND Patient has:		
Worsening gas exchange (for example: $O_2$ desaturations [for example pulse oximetry < 94%], increased oxygen requirements, or increased ventilator demand)		
AND Patient has at least <i>three</i> of the following:		



•	Temperature instability		1
•	Leukopenia ( $\leq$ 4000 WBC/mm3) <u>or</u> leukocytosis ( $\geq$ 15,000 WBC/mm3) and left shift ( $\geq$ 10% band forms)		
•	New onset of purulent sputum <sup>3</sup> or change in character of sputum <sup>4</sup> , or increased respiratory secretions, or increased suctioning requirements		
•	Apnea, tachypnea <sup>5</sup> , nasal flaring with retraction of chest wall, or nasal flaring with grunting		
•	Wheezing, rales <sup>6</sup> , or rhonchi		
•	Cough		<del>-</del>
•	Bradycardia (< 100 beats/min) or tachycardia (> 170 beats/min)		
	PNU1: ALTERNATE CRITERIA, for child > 1 year old or ≤ 12 years old		
Element		Element Met	Date
Patient has	s one of the following found in two or more serial chest imaging test results 1, 2, 14:		
Either new	and persistent <b>OR</b> progressive and persistent		
•	Infiltrate		
•	Consolidation		
•	Cavitation		
NOTE: In n	atients <b>without</b> underlying pulmonary or cardiac disease (such as respiratory distress s	undrome	
bronchopu	lmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), <u>one d</u> is acceptable <sup>1</sup> .		est imaging
	nt has at least <u>three</u> of the following:		
AITD TUTIES	Fever (> 38. 0°C or > 100. 4°F) or hypothermia (< 36. 0°C or < 96. 8°F)		
•	Leukopenia (≤ 4000 WBC/mm³) or leukocytosis (≥ 15,000 WBC/mm³)		
•	New onset of purulent sputum <sup>3</sup> or change in character of sputum <sup>4</sup> , or increased		
•	respiratory secretions, or increased suctioning requirements		1
•	New onset or worsening cough, or dyspnea, or apnea, or tachypnea <sup>5</sup>		
•	Rales <sup>6</sup> or bronchial breath sounds		
•	Worsening gas exchange (for example: O <sub>2</sub> desaturations [for example pulse		
	oximetry < 94%], increased oxygen requirements, or increased ventilator demand)		
Notes/Con	nments:	ı	



Documentation Review Checklist		
Pneumonia 2 (PNU2)		
PNU2: Specific Site Algorithms for Pneumonia with Common Bacterial or Filamentous F		hogens and
Specific Laboratory Findings		
Element	Element	Date
	Met	
Patient has <i>one of the following</i> found in two or more serial chest imaging test results 1.2.14:		
Either new and persistent <b>OR</b> progressive and persistent	,	
Infiltrate		
Consolidation		
Cavitation		
<ul> <li>Pneumatoceles, in infants ≤ 1 year old</li> </ul>		
NOTE: In patients without underlying pulmonary or cardiac disease (such as respiratory distress s	yndrome,	
bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), one test result is acceptable $^{1}$ .	<u>definitive</u> cl	hest imaging
AND Patient has at least <u>one</u> of the following:		
• Fever (> 38.0°C or > 100.4°F)		
• Leukopenia (≤ 4,000 WBC/mm³)		
Leukocytosis (≥ 12,000 WBC/mm³)		
<ul> <li>Adults ≥ 70 years old, altered mental status with no other recognized cause</li> </ul>		
AND Patient has at least <i>one</i> of the following:		
<ul> <li>New onset of purulent sputum<sup>3</sup> or change in character of sputum<sup>4</sup>, or increased</li> </ul>		
respiratory secretions, or increased suctioning requirements	ļ	
<ul> <li>New onset or worsening cough, or dyspnea, or tachypnea<sup>5</sup></li> </ul>		
<ul> <li>Rales<sup>6</sup> or bronchial breath sounds</li> </ul>		
<ul> <li>Worsening gas exchange (for example: O<sub>2</sub> desaturations (for example,</li> </ul>		
$PaO_2/FiO_2 \le 240)^2$ , increased oxygen requirements, or increased ventilator		
demand)		
AND Patient has at least <u>one</u> of the following:		
Organism identified from blood <sup>8,13</sup>		
Organism identified from pleural fluid <sup>9,13</sup>		
Positive quantitative culture or corresponding semi-quantitative culture result		
from minimally-contaminated LRT specimen ( <i>specifically BAL, protected specimen</i>	ļ	
brushing, or endotracheal aspirate)		
<ul> <li>≥ 5% BAL-obtained cells contain intracellular bacteria on direct microscopic exam (for example: Gram's stain)</li> </ul>	🗀	
Positive quantitative culture or corresponding semi-quantitative culture result <sup>9</sup> of		<del> </del>
lung tissue		
<ul> <li>Histopathologic exam shows at least <u>one</u> of the following evidences of pneumonia:</li> </ul>		
Abscess formation or foci of consolidation with intense PMN accumulation		
in bronchioles and alveoli		
<ul> <li>Evidence of lung parenchyma invasion by fungal hyphae or pseudohyphae</li> </ul>		
Notes/Comments:		



Documentation Review Checklist		
Pneumonia 2 (PNU2)		
PNU2: Specific Site Algorithms for Viral, Legionella, and other Bacterial Pneumoni	as with De	finitive
Laboratory Findings		
Element	Element	Date
Detient has are of the following found in two or more social short imaging test results 1, 2, 14,	Met	
Patient has <i>one of the following</i> found in two or more serial chest imaging test results <sup>1,2,14</sup> :  Either new and persistent <b>OR</b> progressive and persistent		
Infiltrate		
Consolidation		
Cavitation		
Pneumatoceles, in infants ≤ 1 year old		
NOTE: In patients <b>without</b> underlying pulmonary or cardiac disease (such as respiratory distress	<u> </u>	
bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), <u>one</u>	•	hest imaaina
test result is acceptable <sup>1</sup> .	<u> </u>	
AND Patient has at least <u>one</u> of the following:		
• Fever (> 38.0°C or > 100.4°F)		
• Leukopenia (≤ 4,000 WBC/mm³)		
Leukocytosis (≥ 12,000 WBC/mm³)		
<ul> <li>Adults ≥ 70 years old, altered mental status with no other recognized cause</li> </ul>		
AND Patient has at least one of the following:		
<ul> <li>New onset of purulent sputum<sup>3</sup> or change in character of sputum<sup>4</sup>, or increased</li> </ul>		
respiratory secretions, or increased suctioning requirements		
<ul> <li>New onset or worsening cough, or dyspnea, or tachypnea<sup>5</sup></li> </ul>		
Rales <sup>6</sup> or bronchial breath sounds		
<ul> <li>Worsening gas exchange (for example: O<sub>2</sub> desaturations (for example,</li> </ul>		
$PaO_2/FiO_2 \le 240)^2$ , increased oxygen requirements, or increased ventilator		
demand)  AND Patient has at least <i>one</i> of the following:		
Virus, Bordetella, Legionella, Chlamydia, or Mycoplasma identified from		<u> </u>
respiratory secretions or tissue by a culture or non-culture based microbiologic		
testing method which is performed for purposes of clinical diagnosis or treatment		
(for example: not Active Surveillance Culture/Testing (ASC/AST))		
Fourfold rise in paired sera (IgG) for pathogen (for example: influenza viruses,		
Chlamydia)		
• Fourfold rise in <i>Legionella pneumophila</i> serogroup 1 antibody titer to ≥ 1:128 in		
paired acute and convalescent sera by indirect IFA		
Detection of <i>L. pneumophila</i> serogroup 1 antigens in urine by RIA or EIA  Notes (Commonts)		
Notes/Comments:		



Documentation Review Checklist			
Pneumonia 3 (PNU3)			
PNU3: Specific Site Algorithms for Pneumonia in Immunocompromised Patients			
Element	Element Met	Date	
Patient has <i>one of the following</i> found in two or more serial chest imaging test results 1.2.14:			
Either new and persistent <b>OR</b> progressive and persistent			
Infiltrate			
Consolidation			
Cavitation			
<ul> <li>Pneumatoceles, in infants ≤ 1 year old</li> </ul>			
NOTE: In patients <b>without</b> underlying pulmonary or cardiac disease (such as respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), one definitive chest imaging test result is acceptable $^{1}$ .			
<u>AND</u> Patient is immunocompromised <sup>10</sup>			
AND Patient has at least <u>one</u> of the following:			
<ul><li>Fever (&gt; 38.0°C or &gt; 100.4°F)</li></ul>			
<ul> <li>Adults ≥ 70 years old, altered mental status with no other recognized cause</li> </ul>			
<ul> <li>New onset of purulent sputum<sup>3</sup> or change in character of sputum<sup>4</sup>, or increased respiratory secretions, or increased suctioning requirements</li> </ul>			
<ul> <li>New onset or worsening cough, or dyspnea, or tachypnea<sup>5</sup></li> </ul>			
<ul> <li>Rales<sup>6</sup> or bronchial breath sounds</li> </ul>			
<ul> <li>Worsening gas exchange (for example: O₂ desaturations [for example: PaO₂/FiO₂ ≤ 240]<sup>7</sup>, increased oxygen requirements, or increased ventilator demand)</li> </ul>			
Hemoptysis			
Pleuritic chest pain			
AND Patient has at least <u>one</u> of the following:	L		
<ul> <li>Identification of matching Candida spp. from blood and one of the following: sputum, endotracheal aspirate, BAL, or protected specimen brushing<sup>11,12,13</sup></li> </ul>			
<ul> <li>Evidence of fungi (excluding any Candida and yeast not otherwise specified) from minimally-contaminated LRT specimen (specifically BAL, protected specimen brushing, or endotracheal aspirate) from one of the following:         <ul> <li>Direct microscopic exam</li> <li>Positive culture of fungi</li> <li>Non-culture diagnostic laboratory test</li> </ul> </li> </ul>			
OR Any of the following from:			
LABORATORY CRITERIA DEFINED UNDER PNU2			
Notes/Comments:			



## **Footnotes to Algorithms:**

- 1. To help confirm difficult cases, multiple imaging test results spanning over several calendar days must be considered when determining if there is imaging test evidence of pneumonia. Pneumonia may have rapid onset and progression but does not resolve quickly. Imaging test evidence of pneumonia will persist. Rapid imaging resolution suggests that the patient does not have pneumonia, but rather a non-infectious process such as atelectasis or congestive heart failure.
  - The diagnosis of healthcare-associated pneumonia may be quite clear on the basis of signs, symptoms and a single definitive chest imaging test result. Therefore, in a patient <u>without</u> underlying pulmonary or cardiac disease and <u>when there is only one imaging test available</u>, if the imaging finding is an eligible and definitive finding, the imaging test evidence requirement can be met.
  - In patients <u>without</u> underlying disease if <u>more than one imaging test is available</u> the serial imaging test results must also be evaluated and must demonstrate persistence of eligible and definitive findings.
  - In patients with underlying pulmonary or cardiac disease (such as interstitial lung disease, congestive heart failure, etc.), the diagnosis of pneumonia may be particularly difficult. For example, imaging findings of pulmonary edema from decompensated congestive heart failure may simulate the presentation of pneumonia. Therefore, in patients with underlying disease, serial chest imaging test results must be examined and must demonstrate persistence of eligible and definitive findings to help separate infectious from non-infectious pulmonary processes.
- 2. Note that there are many ways of describing the imaging appearance of pneumonia. Examples include, but are not limited to, "air-space disease", "focal opacification", "patchy areas of increased density". Although perhaps not specifically delineated as pneumonia by the radiologist, in the appropriate clinical setting these alternative descriptive wordings should be seriously considered as potentially positive findings. If provided and the findings are not documented as attributed to another issue (for example, pulmonary edema, chronic lung disease) they are eligible for meeting imaging test evidence of pneumonia.
- 3. Purulent sputum is defined as secretions from the lungs, bronchi, or trachea that contain ≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field (x100). Refer to the <u>table below</u> if your laboratory reports these data semi-quantitatively or uses a different format for reporting Gram stain or direct examination results (for example, "many WBCs" or "few squamous epithelial cells"). This laboratory confirmation is required since written clinical descriptions of purulence are highly variable.



How do I use the purulent respiratory secretions criterion if	Instruction
My laboratory reports counts of "white blood cells" or "polymorphonuclear leukocytes" or "leukocytes" rather than counts of "neutrophils"?	Assume that counts of cells identified by these other descriptors (for example, "white blood cells") are equivalent to counts of neutrophils, unless the laboratory tells you this is not the case.
My laboratory reports semi-quantitative results (not quantitative results) for numbers of neutrophils and squamous epithelial cells?	Check with the laboratory to get information about what quantitative ranges the semi-quantitative reports correspond to.
My laboratory cannot provide additional information on how its semi-quantitative reporting corresponds to quantitative reporting ranges for neutrophils and squamous epithelial cells?	Use the following direct examination results to meet the purulent respiratory secretions criterion: many, heavy, numerous, $4+$ , or $\geq 25$ neutrophils per low power field (lpf) [x100], AND no, rare, occasional, few, $1+$ or $2+$ , or $\leq 10$ squamous epithelial cells per lpf [x100].
My laboratory reports <u>only</u> the numbers of neutrophils present, without reporting the number of squamous epithelial cells?	In this situation, the purulent secretions criterion may be met using the specified quantitative and semi-quantitative thresholds for neutrophils alone (specifically many, heavy, numerous, $4+$ , or $\geq 25$ neutrophils per lpf [x100]).
My laboratory uses different reporting thresholds for neutrophils and squamous epithelial cells (for example, maximum report of $\geq$ 20 neutrophils per low power field [x100], or minimum report of $\leq$ 15 squamous epithelial cells per low power field [x100])?	In this situation, the purulent secretions criterion may be met using the laboratory's specified maximum quantitative threshold for neutrophils, and/or minimum quantitative threshold for squamous epithelial cells.
My laboratory processes respiratory specimens such as bronchoalveolar lavage fluid using a centrifugation procedure (for example, "cytospin"), and there is no quantitation or semi-quantitation of neutrophils or white blood cells in the direct examination report?	In this situation, a report indicating the presence of white blood cells, without quantitation, is sufficient to meet the purulent secretions criterion.

- 4. Change in character of sputum refers to the color, consistency, odor, and quantity.
- 5. In adults, tachypnea is defined as respiration rate > 25 breaths per minute. Tachypnea is defined as > 75 breaths per minute in premature infants born at < 37 weeks gestation and until the 40th week; > 60 breaths per minute in patients < 2 months old; > 50 breaths per minute in patients 2-12 months old; and > 30 breaths per minute in children > 1 year old.
- 6. Rales may be described as "crackles".
- 7. This measure of arterial oxygenation is defined as the ratio of the arterial tension ( $PaO_2$ ) to the inspiratory fraction of oxygen ( $FiO_2$ ).
- 8. Any coagulase-negative *Staphylococcus* species, any *Enterococcus* species and any *Candida* species or yeast not otherwise specified that are identified from blood cannot be deemed secondary to a PNEU event, unless the organism was also identified from lung tissue or pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; a pleural fluid specimen collected after a chest tube is repositioned or from a chest tube in place > 24 hours is not eligible). This applies when meeting PNU2 or when meeting PNU3 (for patients meeting the immunocompromised definition) with the laboratory findings found in PNU2. Identification of matching *Candida* spp. from blood and sputum, endotracheal aspirate, BAL, or protected specimen brushing with specimen collection dates in the same IWP (see <u>footnote 11</u>) can be used to satisfy PNU3 definition for patients meeting the immunocompromised definition (see <u>footnote 10</u>).



- Refer to threshold values for cultured specimens (lung tissue, BAL, protected specimen brushing, or endotracheal aspirate) with growth of eligible pathogens (<u>Table 5</u>).
   Notes:
  - A specimen that is not obtained through an artificial airway (specifically an endotracheal tube or a
    tracheostomy) is not considered minimally contaminated and is not eligible for use in meeting the
    laboratory criteria for PNEU (PNU2 or PNU3 when using the laboratory findings found in PNU2). Sputum or
    tracheal secretions collected from a non-ventilated patient are not minimally-contaminated specimens.
  - The following organisms can only be used to meet PNEU definitions when identified from lung tissue or pleural fluid obtained during thoracentesis or within 24 hours of chest tube placement (not from a chest tube that has been repositioned or from a chest tube that has been in place > 24 hours):
    - Any coagulase-negative *Staphylococcus* species
    - Any Enterococcus species
    - Any Candida species or yeast not otherwise specified. <u>Exception</u>: identification of matching Candida spp. from blood and sputum, endotracheal aspirate, BAL, or protected specimen brushing with specimen collection dates in the same IWP can be used to satisfy PNU3 definition for immunocompromised patients (see footnote 10).

Table 5: Threshold values for cultured specimens used in the diagnosis of pneumonia

Specimen collection/technique	Values*
Lung tissue <sup>†</sup>	≥ 10 <sup>4</sup> CFU/g tissue
Bronchoscopically (B) obtained specimens	
Bronchoalveolar lavage (B-BAL)	≥ 10 <sup>4</sup> CFU/ml
Protected BAL (B-PBAL)	≥ 10 <sup>4</sup> CFU/mI
Protected specimen brushing (B-PSB)	≥ 10 <sup>3</sup> CFU/ml
Nonbronchoscopically (NB) obtained (blind) specimens	
NB-BAL	≥ 10 <sup>4</sup> CFU/ml
NB-PSB	≥ 10 <sup>3</sup> CFU/ml
Endotracheal aspirate (ETA)	≥ 10 <sup>5</sup> CFU/ml

CFU = colony forming units

g = gram ml = milliliter

## 10. Immunocompromised patients include only

- those with neutropenia defined as absolute neutrophil count or total white blood cell count (WBC)
   500/mm3
- those with leukemia, lymphoma or who are HIV positive with CD4 count < 200</li>
- those who have undergone splenectomy
- those who have a history of solid organ or hematopoietic stem cell transplant
- those on cytotoxic chemotherapy
- those on enteral or parenteral administered steroids (exclude inhaled and topical steroids) daily for > 14
  consecutive days on the date of event



<sup>\*</sup>Consult with your laboratory to determine if reported semi-quantitative results match the quantitative thresholds. In the absence of additional information available from your laboratory, a semi-quantitative result of "moderate" or "heavy" or "many" or "numerous" growth, or 2+, 3+ or 4+ growth is considered to correspond.
†Open-lung biopsy specimens and immediate post-mortem specimens obtained by transthoracic or transbronchial biopsy

- 11. Blood specimen and respiratory specimen (sputum, endotracheal aspirate, BAL, or protected specimen brushing) must have a collection date that occurs within the IWP.
- 12. Semi-quantitative or non-quantitative cultures of sputum obtained by deep cough, induction, aspiration, or lavage are acceptable.
- 13. Identification of organism by a culture or non-culture based microbiologic testing method, which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing (ASC/AST)).
- 14. If the imaging test result is equivocal for pneumonia, check to see if subsequent imaging tests are definitive. For example, if a chest imaging test result states infiltrate vs. at electasis and a subsequent imaging test result is definitive for infiltrate the initial imaging test would be eligible for use. In the absence of finding a subsequent imaging result that clarifies the equivocal finding, if there is clinical correlation (see <a href="Chapter 16">Chapter 16</a>) then the equivocal imaging test is eligible for use.

